Legend Biotech Corporation (LEGN) Revenue History
Annual and quarterly revenue from 2017 to present
LEGN Revenue Over Time (2017–2025)
LEGN Revenue Growth History
7 of 8 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- +108.2%
- FY2019 revenue growth
- +25.8%
- FY2020 revenue growth
- +21.4%
- FY2021 revenue growth
- -8.2%
- FY2022 revenue growth
- +70.0%
- FY2023 revenue growth
- +143.7%
- FY2024 revenue growth
- +120.0%
- FY2025 revenue growth
- +64.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $305.1M | +56.4% |
| Q4 2025 | $306.4M | +64.3% |
| Q3 2025 | $272.3M | +70.0% |
| Q2 2025 | $255.1M | +36.7% |
| Q1 2025 | $195.1M | +107.5% |
| Q4 2024 | $186.5M | +134.7% |
| Q3 2024 | $160.2M | +66.9% |
| Q2 2024 | $186.5M | +154.4% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2021)
LEGN's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
By Geography
LEGN Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 23, 2026, Legend Biotech Corporation (LEGN) generated trailing twelve-month (TTM) revenue of $1.14 billion, reflecting explosive growth of +56.4% year-over-year. The most recent quarter (Q1 2026) recorded $305.1 million in revenue, down 0.4% sequentially.
Historical Growth Trajectory
LEGN's 5-year compound annual growth rate (CAGR) stands at +68.8%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +106.4% exceeds the 5-year average, indicating an acceleration in the most recent period. Legend Biotech Corporation's highest annual revenue of $1.03 billion was recorded in 2025, an all-time high.
Revenue by Segment
LEGN's revenue is primarily driven by Licensing Of Intellectual Property (100%). With over half of revenue concentrated in Licensing Of Intellectual Property, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including FATE (-52.6% YoY), CRSP (-88.9% YoY), and BEAM (+108.0% YoY) — LEGN has outperformed the peer group in revenue growth. Compare LEGN vs FATE →
LEGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LEGNCurrent | $1.1B | +56.4% | +68.8% | -13.3% | |
 FATE | $7M | -52.6% | -26.7% | -2222.4% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 NTLA | $68M | +45.0% | +3.1% | -651.7% | |
 EDIT | $41M | +8.0% | -14.9% | -245.2% |
LEGN Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.03B | +64.0% | $620.8M | 60.3% | $-136,500,000 | -13.3% |
| 2024 | $627.2M | +120.0% | $392.7M | 62.6% | $-303,243,000 | -48.3% |
| 2023 | $285.1M | +143.7% | $140.9M | 49.4% | $-439,485,000 | -154.1% |
| 2022 | $117.0M | +70.0% | $51.6M | 44.1% | $-455,620,000 | -389.4% |
| 2021 | $68.8M | -8.2% | $68.8M | 100.0% | $-392,287,000 | -570.0% |
| 2020 | $75.0M | +21.4% | $75.0M | 100.0% | $0 | - |
| 2019 | $61.8M | +25.8% | $61.8M | 100.0% | $-132,514,000 | -214.4% |
| 2018 | $49.1M | +108.2% | $49.1M | 100.0% | $-1,534,000 | -3.1% |
| 2017 | $23.6M | - | $23.7M | 100.4% | $13.8M | 58.4% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LEGN — Frequently Asked Questions
Quick answers to the most common questions about buying LEGN stock.
Is LEGN's revenue growth accelerating or slowing?
LEGN revenue growth is accelerating. TTM revenue reached $1.1B, up +56.4% year-over-year — ahead of the 5-year CAGR of +68.8%. This indicates the business is expanding faster than its historical baseline.
What is LEGN's revenue history from 2017 to 2026?
Legend Biotech Corporation (LEGN) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $1.1B, growing at +56.4% YoY. The 5-year CAGR is +68.8%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is LEGN's long-term revenue growth rate (CAGR)?
Legend Biotech Corporation's 5-year revenue CAGR of +68.8% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +56.4% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for LEGN.
Why does LEGN's quarterly revenue fluctuate?
LEGN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Legend Biotech Corporation's revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is LEGN's revenue distributed by segment?
LEGN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does LEGN's revenue compare to industry peers?
Legend Biotech Corporation (LEGN) with TTM revenue of $1.1B and +56.4% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.